AMSTERDAM–(BUSINESS WIRE)–Synaffix B.V., a Dutch biotechnology company focused on the advancement
of its clinical-stage antibody-drug conjugate (ADC) technology for the
development of best-in-class ADCs, announces that ADC Therapeutics has
triggered a third target-specific license under its existing Commercial
License Agreement dated October 2016.
This license provides ADC Therapeutics with the rights to Synaffix’s
proprietary GlycoConnect™ site-specific antibody-drug conjugation and
HydraSpace™ polar spacer technologies to develop and commercialize a
third product candidate against a specific target.
Under the terms of the agreement, Synaffix is eligible to receive
upfront, milestone and royalty payments on a per-target basis. Further
financial details were not disclosed.
Peter van de Sande, CEO of Synaffix said:
“We are very pleased with our collaboration, the rapid progress made by
ADC Therapeutics and the successive expansion to date. This third
target-specific license taken out by ADC Therapeutics provides further
validation of our ADC technology. Since we reached our license
agreement, Synaffix’s GlycoConnect™ and HydraSpace™ technologies have
continued to demonstrate their ability to generate exceptional ADC
product candidates in terms of therapeutic index.”
“2019 has been a tremendous year so far for Synaffix. The first ADC
Therapeutics product candidate generated using our technology reached
the clinic in January 2019 and we have signed additional commercial
license agreements with other partners – Mersana Therapeutics, USA and
Shanghai Miracogen, China. We look forward to continuing our close
collaboration with our license partners, enabling their best-in-class
ADCs and expanding our list of collaborations further.”
– Ends –
Notes to Editors
About GlycoConnect™ and HydraSpace™
The clinical-stage GlycoConnect™ and HydraSpace™ technologies enable
best-in-class ADCs with significantly enhanced efficacy and
tolerability. GlycoConnect™ is the conjugation technology that exploits
the native glycan for site-specific and stable payload attachment.
HydraSpace™ is the compact and highly polar spacer technology. These
technologies can be applied directly to any existing antibody without
any protein engineering and are compatible with all ADC payload classes.
The growing experience of Synaffix and its collaboration partners
continues to confirm the ability of GlycoConnect™ and HydraSpace™ to
consistently generate ADCs that are more effective and better tolerated
when compared to the three major clinical-stage ADC conjugation
technologies.
About Synaffix B.V.
Synaffix B.V. is a Dutch biotechnology company that enables highly
competitive ADC product candidates using its clinical-stage,
site-specific ADC technology platform. In addition to GlycoConnect™ and
the ADC-enhancing HydraSpace™ technology, the extension of the platform
with toxSYN™ payloads provides a fully complimentary technology platform
that enables any company with an antibody to develop superior,
proprietary ADC products.
The Synaffix platform comes with an IND-ready CMC package to support a
rapid timeline to the clinic. Granted patents covering Synaffix’s
technology provide end-to-end protection of the platform technology as
well as resulting products through at least 2035. The business model of
Synaffix is target-specific technology out-licensing as exemplified
through its existing deals with Shanghai Miracogen, Mersana Therapeutics
and ADC Therapeutics.
Synaffix is backed by a top tier, European, life science-focused
investor syndicate that includes Aravis, BioGeneration Ventures, BOM
Capital and M Ventures.
For more information, please visit the website at www.synaffix.com.
Contacts
Synaffix BV Contact
Anthony DeBoer
Director, Business
Development
bd@synaffix.com
Instinctif Partners
Melanie Toyne-Sewell / Phil Marriage
Tel
: +44 207 457 2020
Synaffix@instinctif.com